An Open Label, Safety Study of Participants With Non-Small Cell Lung Cancer Receiving Second-Line Nivolumab Monotherapy in Asia
Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 26 Nov 2017
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Acronyms CheckMate870
- Sponsors Bristol-Myers Squibb
- 10 Nov 2017 Planned initiation date changed from 26 Oct 2017 to 1 Dec 2017.
- 15 Oct 2017 Trial design presented at the 18th World Conference on Lung Cancer.
- 03 Oct 2017 Planned initiation date changed from 30 Sep 2017 to 26 Oct 2017.